Lycia Therapeutics, Inc. LYCA
31.44 USD +0.14 (+0.45%)
At closeNov 11, 2026, 4:00 PM EST
31.44 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
31.01 Day range 33.56
25.05 52-week range 31.44
- YTD
- +4.80%
- 1 year
- +4.80%
News
globenewswire.com Lycia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel…
globenewswire.com Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of…
barrons.com Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere As investors wait for the Claude developer to file its official IPO paperwork, several biotechs are going public and doing just fine.
seekingalpha.com U.S. IPO Weekly Recap: Trickle Of Biotech Activity Continues Amid Tech Sell-Off One biotech IPO debuted this week, while four IPOs submitted initial filings, including two sizable biotech filings. One IPO is currently scheduled for the week ahead as investors continue to hold…
globenewswire.com Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of…
reuters.com Drug developer Lycia Therapeutics targets $938 million valuation in US IPO Drug developer Lycia Therapeutics targets $938 million valuation in US IPO